中文

宏源药业 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-29
ItemAmountY/Y
Revenue¥0.70B+62.3%
Gross profit¥0.23B
Operating income¥0.18B
Net income¥0.14B+1534.3%
Gross margin32.0%Net margin 20.5%
Revenue Q/Q+13.0%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.48B68.0%
R&D¥0.03B4.2%
SG&A¥0.03B4.0%
Tax & other¥0.04B5.6%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

杰创智能威尔高同星科技通力科技华融化学普蕊斯富士莱艾布鲁格力博恒工精密海看股份泰恩康

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies